Cassava Announces Dr. Jim Kupiec’s Retirement As Chief Medical Officer And Dr. Jack Moore’s Appointment As Senior Vice President Of Clinical Development

Cassava Sciences, Inc., a biotechnology company focused on developing new treatments for central nervous system (CNS) disorders, has announced that James W. Kupiec, MD, will retire from his role as Chief Medical Officer on May 9, 2025. In his place, Jack Moore, PhD, will join the company as Senior Vice President of Clinical Development starting April 28, 2025. Dr. Moore will report directly to Rick Barry, the CEO.

Rick Barry, President and Chief Executive Officer of Cassava, stated, “The entire Cassava team is grateful for Jim’s service as our Chief Medical Officer. He is retiring after a notable career of exemplary work, with exceptional expertise in Alzheimer’s disease drug development. Thanks to Jim’s attention to patient care and his deep credibility in the scientific community, Cassava completed a high-quality clinical trial program in Alzheimer’s disease that was carried out with respect for the dignity of patients and their caregivers. We wish Jim a happy and fulfilling retirement.”

Mr. Barry mentioned, “As we formulate our strategy going forward, we are pleased to have Jack on board. He brings broad medical affairs and clinical development expertise, plus extensive experience working with study sites and patient advocacy groups. These skills will be invaluable to Cassava as we take the next steps in our TSC program, identify potential clinical collaborators and study sites, and explore additional potential applications.”

“I am eager to contribute my clinical development expertise to Cassava’s emerging program for simufilam in TSC and other applications,” commented Dr. Jack Moore, SVP, Clinical Development of Cassava.

In his new role, Dr. Moore will oversee the clinical development of simufilam, a treatment currently being evaluated for various CNS disorders, including epilepsy related to tuberous sclerosis complex (TSC). Dr. Moore brings a wealth of experience from his work with top global pharmaceutical companies, where he helped advance novel treatments for CNS conditions.